Study of SOC Plus IVIG Compared to SOC Alone in the Treatment of COVID-19

Completed · Phase 4

Conditions studied: Sars-CoV2

In brief

The purpose of this research is to see if Intravenous Immunoglobulin (IVIG) can help reduce respiratory complications (respiratory failure and need for a ventilator) caused by coronavirus disease 2019 (COVID-19). The principal investigator has successfully utilized IVIG for patients infected with the influenza virus. The investigator wants to find out if IVIG is equally effective in COVID-19 infection patients, and if IVIG will give the immune system some help to clear the infection naturally.

Key facts

Study ID
NCT04411667
Run by
George Sakoulas, MD
People needed
34
Starts
2020-04-28
Expected to finish
2020-06-23
Last updated by the study team
2021-06-25

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.